Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

Published Date: 10 Jan 2025

Phase III data show promising efficacy with manageable toxicity and feasible delivery

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

2.

According to new studies, some cancer patients can safely forego radiation therapy.

3.

Second opinions don't significantly delay breast cancer treatment

4.

Pickleball program boosts health and wellness for cancer survivors, study finds

5.

'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot